Biosimilar Monoclonal Antibodies: World Market Prospects 2013-2023

NEW YORK, Sept. 2, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Biosimilar Monoclonal Antibodies: World Market Prospects 2013-2023

http://www.reportlinker.com/p01609813/Biosimilar-Monoclonal-Antibodies-World-Market-Prospects-2013-2023.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biopharmaceutical

Report Details

Biosimilar monoclonal antibodies - this new study shows you potential sales

What does the future hold for biosimilar therapeutic antibodies? Visiongain's new report predicts revenues to 2023. There you find the best places for sales growth, also understanding trends and opportunities.

In that study you get revenue forecasts at overall world market, submarket, product, and national level. See what's happening for those technologies, finding how you can gain.

Read on, then, to explore biosimilar monoclonal antibodies (mAbs) and see what their future market could be worth.

Forecasts to 2023 and other analyses show you commercial potentials

Besides revenue forecasting, our new work shows recent results, growth rates, and market shares. You discover original quantitative and qualitative analysis, seeing business outlooks and developments (R&D). You also get 69 tables, 52 charts, and two research interviews.

Is finding data for biosimilar mAbs a challenge? Avoid falling behind. You can now stay ahead in knowledge, benefiting your research, analyses, and decisions. Also save time.

There you investigate follow-on protein technology for antibodies. You hear what's happening and see where the money lies. Finding that data just got easier.

The following sections, then, show what you get in our research and analysis.

Prospects for the world market and submarkets for those follow-on biologics

Our new report shows revenue to 2023 for the overall world market. It also shows you individual forecasts of seven biosimilar mAb submarkets:• Infliximab• Rituximab• Adalimumab• Trastuzumab• Bevacizumab• Abciximab• Other molecules (grouped analysis).

How will the biosimilar mAbs market expand? Which parts will most prosper? There you assess prospects for revenue growth.

Our study gives you a feel for what stimulates and restrains that industry and market. That analysis helps you identify potential and find ways for your business to develop.

You also find revenue predictions for products using follow-on antibody technology.

Forecasts for 13 agents - assess potential of existing and expected products

How will products perform to 2023 at world level? Our report forecasts individual revenues of 13 biosimilar antibodies, launched or in development, including these:

• Celltrion's Remsima

• Dr. Reddy's Reditux

• Epirus Biopharmaceuticals' BOW-015

• Boehringer Ingelheim's BI695500 and BI695501

• Fujifilm Kyowa Kirin Biologics' forms of adalimumab and bevacizumab

• Biocon's Bmab200

• BIOCAD's BCD-022

• Isu Abxis's Clotinab

• Reliance Life Sciences' R-TPR-019.

There you discover how high sales can go, to 2023, finding products and years with highest predicted growth and revenues. Also you compare competitors. You see what's happening, then, understanding trends, competition, challenges, and opportunities.

Our investigation also divides its overall world forecast into geographical regions.

National markets - what outlooks for sales?

Developments worldwide expand the biosimilar mAbs market. Hear about the best revenue prospects.

In developed and developing countries, many opportunities for producers of those biological drugs will occur from 2013 to 2023. See where and how.

Our analyses show you individual revenue forecasts to 2023 for 12 national markets:

• US and Japan

• Germany, France, UK, Italy, and Spain (EU5)

• China, India, Brazil, Russia (BRIC), and South Korea.

There you discover progress and outlooks. Product launches from 2013 to 2023 will change the commercial landscape. See how, finding what affects that biologics segment.

Issues affecting biosimilar antibody manufacturing and selling

Our report also shows you issues and events affecting that industry and market from 2013, including these:• Demand for biosimilars - rising production needs• Research and development (R&D) for those protein-based medicines• FDA biosimilar guidelines and state regulation of biosimilar substitution• Legal challenges for those substitute drugs• Biobetters as a threat to biosimilars• EMA regulations, and those of other regions• Collaboration in follow-on mAb development• Big pharma and the biosimilar mAbs market.

There you explore political, economic, social, and technological questions, assessing outlooks for the business. You also analyse that industry's strengths, weaknesses, opportunities, and threats. Discover now what the future holds.

Biosimilar antibody-based therapies - what's the 2018 market value?

What happens next? From this decade onwards, follow-on treatments hold great potential for investment and revenues. Our study predicts the world market for biosimilar mAbs will reach $3,229m in 2018, with high growth from 2013 to 2023.

In 2012, monoclonal antibodies formed five of the top ten medicines worldwide by revenue. For those therapies, high potential for biosimilar competition exists. Our analysis predicts those competitors of the leading mAb drugs will be on sale by 2018.

Prospects for mAb biosimilars are strong, then, and from 2013 there will arise many opportunities. Our analysis shows you the possibilities, helping you stay ahead.

Nine ways Biosimilar Monoclonal Antibodies: World Market Prospects 2013-2023 helps you

To sum up, our report gives you the following knowledge:

• Revenue to 2023 of the world market for biosimilar mAbs - discover that industry's overall sales potential

• Revenues to 2023 for 7 world-level submarkets - investigate the potential of its components, finding the most promising places for investments and sales

• Revenues to 2023 for 13 follow-on protein products - find sales outlooks for top brands, and expected agents, seeing how they can compete and succeed

• Forecasts to 2023 for 12 national markets in the Americas, Europe, and Asia - discover the best countries for revenues and potential growth

• Assessments of top companies - hear about participants' activities, capabilities, results, and outlooks

• Review of R&D - explore progress in research and development, finding technological and commercial possibilities

• Interviews with authorities in the industry - discover debates and opinions to help you stay ahead

• Analysis of what stimulates and restrains that industry and market - assess challenges and strengths, helping you compete and get advantages

• Prospects for established competitors and firms seeking to enter that sector - explore needs, practices, and outlooks for future success.

Information found nowhere else

That work gives independent analysis. You receive business intelligence found only in our new report, discovering where prospects are most rewarding.

With our study you are less likely to fall behind in knowledge or miss opportunity. See there how you could benefit your research, analyses, and decisions. Also find how you can save time and get recognition for commercial insight.

Biosimilar mAbs - assess their potentials now, seeing what you can gain

Our study shows you data, trends, opportunities, and sales predictions for biosimilar mAbs. Avoid missing out - please order our new report now.

Visiongain is a trading partner with the US Federal Government

CCR Ref number: KD4R6

Table of Contents

1. Executive Summary

1.1 What This Report Covers

1.2 Biosimilar MAbs: World Market Overview 2013-2023

1.3 Chapter Outlines

1.4 Research and Analysis Methods

2. Introduction to Biosimilar Monoclonal Antibodies

2.1 Natural Antibodies: Key to the Immune System2.2 From Serum Therapy to Monoclonal Antibodies (MAbs)2.3 Humanising the MAb2.4 Biologics and Biosimilars2.5 Why are Biosimilars in Demand?2.6 Considerations for the Development of Biosimilars2.6.1 Biologics and Biosimilars Are Large, Complex Molecules2.6.2 How Big a Concern Is Immunogenicity?2.7 Biosimilar Monoclonal Antibodies Already on the Market

3. World Market Prospects for Biosimilar Monoclonal Antibodies, 2013-2023

3.1 The World Market for Biosimilar Monoclonal Antibodies in 2012: 3 Biosimilar MAbs on the Market

3.2 The World Market for Biosimilar MAbs: An Overarching Revenue Forecast, 2013-2023

3.3 The World Market for Biosimilar MAbs by Compound: Revenue and Market Share Predictions, 2018 and 2023

3.4 The World Market for Biosimilar MAbs by Compound: Grouped Revenue Forecast, 2013-2023

3.4.1 Will Biosimilar Versions of Monoclonal Antibodies Capture a Large Proportion of the Market?

3.4.2 Biosimilar Infliximab: High Growth Expected in 2013

3.4.2.1 Biosimilar Infliximab: Revenue Forecast, 2013-2023

3.4.3 Biosimilar Rituximab: With So Many Compounds Under Development, Will Growth Be Driven or Restrained?

3.4.3.1 Biosimilar Rituximab: Revenue Forecast, 2013-2023

3.4.4 Biosimilar Abciximab: Low Market Incentive Means Few Compounds Are in Development

3.4.4.1 Biosimilar Abciximab: Revenue Forecast, 2013-2023

3.4.5 Biosimilar Trastuzumab: The 4th Biosimilar MAb to Enter the Market

3.4.5.1 Biosimilar Trastuzumab: Revenue Forecast, 2013-2023

3.4.6 Biosimilar Adalimumab: Great Incentive to Develop Biosimilar Versions of the Leading Drug of 2012

3.4.6.1 Biosimilar Adalimumab: Revenue Forecast, 2013-2023

3.4.7 Biosimilar Bevacizumab: Will Late Entry to the Market Restrict Revenue Generation?

3.4.7.1 Biosimilar Bevacizumab: Revenue Forecast, 2013-2023

3.5 Large Market Potential to Drive Growth to 2023

3.6 What Will Restrain the Growth of the Biosimilar MAbs Market Between 2013 and 2023?

4. Promising Biosimilar MAb Products and Their Predicted Future Success, 2013-2023

4.1 Biosimilar Versions on the Market: Remsima Dominates in 20124.1.1 Celltrion's Remsima (infliximab): The First Official Biosimilar Monoclonal Antibody4.1.2 Dr. Reddy's Reditux (rituximab): Are US and EU Approval Expected?4.1.3 Probiomed's Kikuzubam (rituximab): On the Market in South America4.1.4 Instas Pharmaceuticals' Mabtas (rituximab)4.1.5 Isu Abxis' Clotinab (abciximab): The First Biosimilar Monoclonal Antibody?4.2 Biosimilar Versions on the Market and Promising Compounds in the Pipeline: Market Forecast, 2013-20234.2.1 Celltrion's Remsima (infliximab): Revenue Forecast, 2013-20234.2.2 Epirus Biopharmaceuticals' BOW-015 (infliximab): Revenue Forecast, 2013-20234.2.3 Dr. Reddy's Reditux (rituximab): Revenue Forecast, 2013-20234.2.4 Boehringer Ingelheim's BI695500 (rituximab): Revenue Forecast, 2013-20234.2.5 Celltrion's CT-P10 (rituximab): Revenue Forecast, 2013-20234.2.6 Boehringer Ingelheim's BI695501 (adalimumab): Revenue Forecast, 2013-20234.2.7 Fujifilm Kyowa Kirin Biologics' adalimumab: Revenue Forecast, 2013-20234.2.8 Fujifilm Kyowa Kirin Biologics' bevacizumab: Revenue Forecast, 2013-20234.2.9 Celltrion's CT-P06 (trastuzumab): Revenue Forecast, 2013-20234.2.10 Biocon's Bmab200 (trastuzumab): Revenue Forecast, 2013-20234.2.11 BIOCAD's BCD-022 (trastuzumab): Revenue Forecast, 2013-20234.2.12 Isu Abxis' Clotinab (abciximab): Revenue Forecast, 2013-20234.2.13 Reliance Life Sciences' R-TPR-019 (abciximab): Revenue Forecast, 2013-2023

5. Leading National Markets for Biosimilar Monoclonal Antibodies, 2013-2023

5.1 What Were the Leading National Markets for Biosimilar Monoclonal Antibody Development in 2012?

5.2 What Were the Leading National Markets for Sales of Biosimilar Monoclonal Antibodies in 2012?

5.3 Which Markets Will Grow Fastest to 2023?

5.4 Market Shares of the Leading National Markets: All Set to Change, 2013-2023

5.5 The Outlook for Biosimilar MAbs in the US, 2013-2023

5.5.1 When Are the Final FDA Biosimilar Guidelines Expected?

5.5.2 Legal Challenges for Biosimilars in the US

5.5.3 State Regulation of Biosimilar Substitution

5.5.4 The US Biosimilar MAb Market: Revenue Forecast, 2013-2023

5.6 The Outlook for Monoclonal Antibody Biosimilars in the EU, 2013-2023

5.6.1 The EU Led the World in Biosimilar Regulation

5.6.2 Updating Biosimilar Regulation: Guidelines for the Specific Approval of Biosimilar MAbs

5.6.3 EMA Simplifies Biosimilar Development in the EU

5.6.4 Biosimilar MAbs: EU Launch in 2014?

5.6.5 Germany: Set to Become the Largest National Market for Biosimilar MAbs in the EU

5.6.6 France: Will the Uptake of Biosimilar MAbs Be Restricted?

5.6.7 UK: Drug Uptake Will Be High

5.6.8 Italy: Healthcare Spending Cuts Will Drive Growth

5.6.9 Spain: High Biosimilar MAb Discounts Expected

5.7 The Outlook for Monoclonal Antibody Biosimilars in China, 2013-2023

5.7.1 China to Release Formal Biosimilar Development Guidelines

5.7.2 China: Becoming the World's Leading Market for Biosimilar MAbs

5.8 The Outlook for Monoclonal Antibody Biosimilars in India, 2013-2023

5.8.1 India Releases New Biosimilar Development Guidelines

5.8.2 Indian Biosimilars Submarket Forecast 2013-2023

5.9 The Outlook for Monoclonal Antibody Biosimilars in Japan 2013-2023

5.9.1 Regulatory Processes for Biosimilars in Japan

5.9.2 Regulations for Naming Biosimilars

5.9.3 Biosimilar MAbs Will Be Launched in Japan in 2016

5.9.4 Japanese Biosimilar Submarket Forecast 2013-2023

5.10 South Korea: The World's leading Nation for Biosimilar MAbs

5.10.1 KFDA Introduced Biosimilar Guidelines in 2009

5.10.2 There Has Been Significant Investment in Biosimilars in South Korea

5.10.3 The Outlook for the South Korean Biosimilar MAb Market, 2013-2023

5.11 Brazil: The Third Leading Nation in the 2012 Biosimilar MAb Market, But What Will The Future Hold?

5.11.1 ANVISA's Biosimilar Regulations Are Similar to the EMA's

5.11.2 The Outlook for Monoclonal Antibody Biosimilars in Brazil, 2013-2023

5.12 The Outlook for Monoclonal Antibody Biosimilars in Russia, 2013-2023

5.12.1 No Specific Biosimilar Legislation Exists in Russia 2013

5.12.2 Russian Government Investing in Development of Biosimilars

5.12.3 Russian Biosimilar MAb Revenue Forecast 2013-2023

6. Leading Companies for Biosimilar MAbs, 2013

6.1 Prominent Companies in the Biosimilar Monoclonal Antibodies Industry, 20136.2 Collaboration in Biosimilar MAb Development6.3 BioXpress: 16 Compounds in the R&D Pipeline6.4 Celltrion: One Compound on the Market and Two in Phase III of Development, and Others Wait In The Wings6.5 Harvest Moon: 6 Compounds Under Development6.6 Gene Techno Science: 6 Compounds Under Development6.7 Mabion: Poland's Leading Biosimilar MAb Developer6.8 India's Biocon: A Quiet Competitor6.9 Pfizer: Big Pharma Is Entering the Biosimilar MAb Market6.10 BIOCAD6.11 Big Pharma and the Biosimilar MAbs Market

7. Qualitative Analysis of the Biosimilar MAbs Market, 2013-2023

7.1 Strengths and Weaknesses of the Biosimilar Monoclonal Antibody Market, 2013

7.1.1 Worldwide Demand for More Affordable Therapies Underpins the Market

7.1.2 The Complexity of the Molecules Engenders a Myriad of Market Weaknesses

7.2 Opportunities and Threats Facing the Biosimilar Monoclonal Antibody Market, 2013-2023

7.2.1 A Well-Stocked Pipeline in the Face of Approaching Patent Expiries: Opportunities for Market Expansion

7.2.2 Competition and Lack of Confidence: Threats to Market Penetration?

7.2.2.1 Biobetters as a Threat to Biosimilars

7.3 Social, Technological, Economic and Political Factors Influencing the Biosimilar Monoclonal Antibodies Market (STEP Analysis) 2013-2023

7.3.1 Social Factors: Driving or Restraining the Market?

7.3.2 Advances in Technology: Producing Biosimilar MAbs Cheaply and Easily

7.3.3 Economic Pressures are Driving the Demand for Biosimilar MAbs

7.3.4 Political Issues: Stringent Regulations are Hurdles to Market Entry

8. Research Interviews

8.1 Interview with Dr Xing Wang, President of Array Bridge8.1.1 On Challenges Surrounding the Development of Biosimilar MAbs8.1.2 On the Services Offered by Array Bridge8.1.3 On the Demand for Biosimilar MAbs8.1.4 On Factors Determining the Success of Biosimilar MAbs8.1.5 On Regulatory Approval of Biosimilar MAbs: The US vs. the EU8.2 Interview With Dr Terence Ryan, SVP, iBio8.2.1 iBio and its Biosimilar Pipeline, 20138.2.2 The iBioLaunch Platform8.2.3 Differences Between Developing Biosimilar and Biologics8.2.4 Product Differentiation in the Biosimilar Market8.2.5 Biosimilars and Immunogenicity8.2.6 Challenges in Developing Biosimilars for the US Market

9. Conclusions

9.1 Biosimilar Monoclonal Antibodies: World Market, 2013-2023

9.2 The Future of Promising Pipeline Compounds

9.3 Leading National Markets for Biosimilar Monoclonal Antibodies, 2013-2023

9.4 Leading Companies in the Industry

9.5 Trends in the Industry and Market

9.5.1 Economic Pressures Stimulate Demand for MAbs

9.5.2 Patent Expiries of Several Blockbuster MAbs Are Approaching, Creating Opportunities for Biosimilars

9.5.3 Complexity of the Molecules Make Production Challenging

9.5.4 Doctor and Patient Doubt Regarding Interchangeability Will Restrict Uptake

9.5.5 Do Biobetters Pose a Threat?

List of Tables

Table 2.1 Classification of Monoclonal Antibodies

Table 2.2 Murine Monoclonal Antibodies on the Market, 2013

Table 2.3 Chimeric Monoclonal Antibodies on the Market, 2013

Table 2.4 Humanised Monoclonal Antibodies on the Market, 2013

Table 2.5 Fully Human Monoclonal Antibodies on the Market, 2013

Table 2.6 Top 10 Prescription Drugs by Revenue ($m), 2012

Table 3.1 The Biosimilar Monoclonal Antibody Market by Compound: Revenue ($m) and Market Share (%), 2012

Table 3.2 Biosimilar MAb World Market: Revenue Forecast ($m), 2012-2023

Table 3.3 The World Market for Biosimilar MAbs: Revenues ($m) and Market Shares (%) by Compound, 2018 and 2023

Table 3.4 Major Originator Biologic Products: EU and US Patent Expiry Dates

Table 3.5 Biosimilar MAbs: Revenue Forecasts ($m) by Molecule, 2012-2023

Table 3.6 Biosimilar Infliximab: Compounds in the Pipeline, 2013

Table 3.7 Biosimilar Infliximab: Revenue ($m) and Market Share (%) Forecast, 2012-2023

Table 3.8 Biosimilar Rituximab: Compounds in the Pipeline, 2013

Table 3.9 Biosimilar Rituximab: Revenue ($m) and Market Share (%) Forecast, 2012-2023

Table 3.10 Biosimilar Abciximab: Compounds in the Pipeline, 2013

Table 3.11 Biosimilar Abciximab: Revenue ($m) and Market Share (%) Forecast, 2012-2023

Table 3.12 Biosimilar Trastuzumab: Compounds in the Pipeline, 2013

Table 3.13 Biosimilar Trastuzumab: Revenue ($m) and Market Share (%) Forecast, 2012-2023

Table 3.14 Biosimilar Adalimumab: Compounds in Development, 2013

Table 3.15 Biosimilar Adalimumab: Revenue ($m) and Market Share (%) Forecast, 2012-2023

Table 3.16 Biosimilar Bevacizumab: Compounds in the Pipeline, 2013

Table 3.17 Biosimilar Bevacizumab: Revenue ($m) and Market Share (%) Forecast, 2012-2023

Table 4.1 Biosimilar MAb Versions on the Market: Revenues ($m) and Market Shares (%), 2012

Table 4.2 Biosimilar Versions on the Market and in the Pipeline: Revenue Forecasts ($m), 2012-2023

Table 4.3 Celltrion's Remsima: Revenue ($m) and Market Share (%) Forecast, 2012-2023

Table 4.4 Epirus Biopharmaceuticals' BOW-015: Revenue ($m) and Market Share (%) Forecast, 2012-2023

Table 4.5 Dr. Reddy's Reditux: Revenue ($m) and Market Share (%) Forecast, 2012-2023

Table 4.6 Boehringer Ingelheim's BI695500: Revenue Forecast, 2012-2023

Table 4.7 Celltrion's CT-P10: Revenue ($m) and Market Share (%) Forecast, 2012-2023

Table 4.8 Boehringer Ingelheim's BI695501: Revenue ($m) and Market Share (%) Forecast, 2012-2023

Table 4.9 Fujifilm Kyowa Kirin Biologics' adalimumab: Revenue ($m) and Market Share (%) Forecast, 2012-2023

Table 4.10 Fujifilm Kyowa Kirin Biologics' bevacizumab: Revenue ($m) and Market Share (%) Forecast, 2012-2023

Table 4.11 Celltrion's CT-P06: Revenue ($m) and Market Share (%) Forecast, 2012-2023

Table 4.12 Biocon's Bmab200: Revenue ($m) and Market Share (%) Forecast, 2012-2023

Table 4.13 BIOCAD's BCD-022: Revenue ($m) and Market Share (%) Forecast, 2012-2023

Table 4.14 Isu Abxis' Clotinab: Revenue ($m) and Market Share (%) Forecast, 2012-2023

Table 4.15 Reliance Life Sciences' R-TPR-019: Revenue ($m) and Market Share (%) Forecast, 2012-2023

Table 5.1 Prominent Companies With 2+ Biosimilar MAbs in Development and Their Country of Origin, 2013

Table 5.2 The Biosimilar MAb Market by Country: Revenues ($m) and Market Shares (%), 2012

Table 5.3 The Biosimilar MAb Market by Country: Grouped Revenue Forecasts ($m), 2012-2023

Table 5.4 The Biosimilar MAb Market: National Market Shares (%), 2013-2023

Table 5.5 The US Biosimilar MAb Market: Revenue ($m) and Market Share (%) Forecast, 2012-2023

Table 5.6 EU5 Biosimilar MAb Markets: Overall Revenue ($m) and Market Share (%) Forecasts by Country, 2012-2023

Table 5.7 The German Biosimilar MAb Market: Revenue ($m) and Market Share (%) Forecast, 2012-2023

Table 5.8 The French Biosimilar MAb Market: Revenue ($m) and Market Share (%) Forecast, 2012-2023

Table 5.9 The UK Biosimilar MAb Market: Revenue ($m) and Market Share (%) Forecast, 2012-2023

Table 5.10 The Italian Biosimilar MAb Market: Revenue ($m) and Market Share (%) Forecast, 2012-2023

Table 5.11 The Spanish Biosimilar MAb Market: Revenue ($m) and Market Share (%) Forecast, 2012-2023

Table 5.12 The Chinese Biosimilar MAb Market: Revenue ($m) and Market Share (%) Forecast, 2012-2023

Table 5.13 The Indian Biosimilar MAb Market: Revenue ($m) and Market Share (%) Forecast, 2012-2023

Table 5.14 The Japanese Biosimilar MAb Market: Revenue ($m) and Market Share (%) Forecast, 2012-2023

Table 5.15 The South Korean Biosimilar MAb Market: Revenue ($m) and Market Share (%) Forecast, 2012-2023

Table 5.16 The Brazilian Biosimilar MAb Market: Revenue ($m) and Market Share (%) Forecast, 2012-2023

Table 5.17 The Russian Biosimilar MAb Market: Revenue ($m) and Market Share (%) Forecast, 2012-2023

Table 6.1 Companies in the Biosimilar MAb Industry by Number of Compounds in Development, 2013

Table 6.2 Selected Collaborations for Biosimilar MAb Development, 2009-2013

Table 6.3 BioXpress: Compounds in the Pipeline, 2013

Table 6.4 The Tests Carried Out By BioXpress During Biosimilar MAb Development and Their Objectives

Table 6.5 Compounds in Celltion's Pipeline: Compound Name, Generic Name, Development Stage and Anticipated Year of Approval, 2013

Table 6.6 Gene Techno Science: Revenue and Gross Profit ($m), Year Ended March 2012 and 2013

Table 6.7 Mabion: Compounds in the Pipeline and Their Development Stage, 2013

Table 6.8 Biocon: Compounds in the Pipeline and Their Stage of Development, 2013

Table 6.9 Pfizer: Compounds in the Pipeline and Their Stage of Development, 2013

Table 6.10 BIOCAD: Compounds in the Pipeline and Their Stage of Development, 2013

Table 6.11 Big Pharma's Positions in the Biosimilar MAb Industry, 2013

Table 7.1 Strengths and Weaknesses of the Biosimilar MAb Market, 2013

Table 7.2 Opportunities and Threats Facing the Biosimilar MAb Market, 2013-2023

Table 7.3 Social, Technological, Economic and Political Factors Influencing the Biosimilar MAb Market (STEP Analysis), 2013-2023

List of Figures

Figure 2.1 Depiction of an Antibody

Figure 3.1 The Biosimilar Monoclonal Antibody Market by Compound: Market Share (%), 2012

Figure 3.2 The World Market for Biosimilar MAbs: Revenue Forecast ($m), 2012-2023

Figure 3.3 The Biosimilar MAb Market: Market Share (%) by Compound, 2018

Figure 3.4 The Biosimilar MAb Market: Market Share (%) by Compound, 2023

Figure 3.5 Biosimilar Infliximab: Revenue Forecast ($m), 2012-2023

Figure 3.6 Biosimilar Rituximab: Revenue Forecast ($m), 2012-2023

Figure 3.7 Biosimilar Abciximab: Revenue Forecast ($m), 2012-2023

Figure 3.8 Biosimilar Trastuzumab: Revenue Forecast ($m), 2012-2023

Figure 3.9 Biosimilar Adalimumab: Revenue Forecast ($m), 2012-2023

Figure 3.10 Biosimilar Bevacizumab: Revenue Forecast ($m), 2012-2023

Figure 3.11 Biosimilar MAbs: Market Drivers and Restraints, 2013-2023

Figure 4.1 Biosimilar MAb Versions on the Market: Market Share (%), 2012

Figure 4.2 Biosimilar MAb Versions on the Market and in the Pipeline: Market Shares (%), 2018

Figure 4.3 Biosimilar MAb Versions on the Market and in the Pipeline: Market Shares (%), 2023

Figure 4.4 Celltrion's Remsima: Revenue Forecast ($m), 2012-2023

Figure 4.5 Epirus Biopharmaceuticals' BOW-015: Revenue Forecast ($m), 2012-2023

Figure 4.6 Dr. Reddy's Reditux: Revenue Forecast, 2012-2023

Figure 4.7 Boehringer Ingelheim's BI695500: Revenue Forecast, 2012-2023

Figure 4.8 Celltrion's CT-P10: Revenue Forecast ($m), 2012-2023

Figure 4.9 Boehringer Ingelheim's BI695501: Revenue Forecast ($m), 2012-2023

Figure 4.10 Fujifilm Kyowa Kirin Biologics' adalimumab: Revenue Forecast ($m), 2012-2023

Figure 4.11 Fujifilm Kyowa Kirin Biologics' bevacizumab: Revenue Forecast ($m), 2012-2023

Figure 4.12 Celltrion's CT-P06: Revenue Forecast, 2012-2023

Figure 4.13 Biocon's Bmab200: Revenue Forecast ($m), 2012-2023

Figure 4.14 BIOCAD's BCD-022: Revenue Forecast ($m), 2012-2023

Figure 4.15 Isu Abxis' Clotinab: Revenue Forecast ($m), 2012-2023

Figure 4.16 Reliance Life Sciences' R-TPR-019: Revenue Forecast ($m), 2012-2023

Figure 5.1 Geographical Distribution (%) of Prominent Compounds Under Development, 2013

Figure 5.2 The Biosimilar MAb Market by Country: Market Shares (%) of Revenue, 2012

Figure 5.3 The Biosimilar MAb Market: National Submarket Shares (%), 2017

Figure 5.4 The Biosimilar MAb Market: National Submarket Shares (%), 2023

Figure 5.5 FDA Biosimilar Guidelines 2012: Key Points

Figure 5.6 Biosimilar MAbs in the US: Revenue Forecast ($m), 2012-2023

Figure 5.7 The EU5 Biosimilar MAb Market: Grouped Revenue Forecast ($m), 2012-2023

Figure 5.8 The EU5 Biosimilar MAb Market: Revenue Forecasts ($m) by Country, 2012-2023

Figure 5.9 The German Biosimilar MAb Market: Revenue Forecast ($m), 2012-2023

Figure 5.10 The French Biosimilar MAb Market: Revenue Forecast ($m), 2012-2023

Figure 5.11 The UK Biosimilar MAb Market: Revenue Forecast ($m), 2012-2023

Figure 5.12 The Italian Biosimilar MAb Market: Revenue Forecast ($m), 2012-2023

Figure 5.13 The Spanish Biosimilar MAb Market: Revenue Forecast ($m), 2012-2023

Figure 5.14 The Chinese Biosimilar MAb Market: Revenue Forecast ($m), 2012-2023

Figure 5.15 The Indian Biosimilar MAb Market: Revenue Forecast ($m), 2012-2023

Figure 5.16 The Japanese Biosimilar MAb Market: Revenue Forecast ($m), 2012-2023

Figure 5.17 The South Korean Biosimilar MAb Market: Revenue Forecast ($m), 2012-2023

Figure 5.18 The Brazilian Biosimilar MAb Market: Revenue Forecast ($m), 2012-2023

Figure 5.19 The Russian Biosimilar MAb Market: Revenue Forecast ($m), 2012-2023

Figure 6.1 Prominent Companies in the Biosimilar MAb Industry: Share (%) of the Pipeline, 2013

Figure 9.1 Prominent Compounds in the Biosimilar MAb Market: Comparison of Revenues ($m), 2013, 2018 and 2023

Figure 9.2 Promising Versions of Biosimilar MAbs: Comparison of Revenues ($m), 2013, 2018 and 2023

Figure 9.3 Leading National Markets: Revenues ($m), 2013, 2018 and 2023

Figure 9.4 Prominent Companies in the Biosimilar MAb Industry: Number of Products in the Pipeline, 2013

Companies Listed

Abbott Laboratories

AbbVie

Aché

Actavis

AET BioTech

Agência Nacional de Vigilância Sanitária (ANVISA)

Amgen

Aprogen

Array Bridge

AstraZeneca

Bayer

BIO

BIOCAD

Biocon

Biogen Idec

Bionovis

BioXpress Therapeutics

Boehringer Ingelheim

Bristol-Myers Squibb

Cell Therapeutics

Celltrion

Coherus BioSciences

Daiichi Sankyo

Dong-A

Dr. Reddy's Laboratories

Egis Pharmaceuticals

Eli Lilly

Emcure

EMS

Epirus Biopharmaceuticals

European Medicines Agency (EMA)

Food and Drug Administration (US FDA)

Fresenius

Fujifilm Kyowa Kirin Biologics

Gedeon Richter

Gene Techno Science

Genentech

Genor Biopharma

GlaxoSmithKline

Glycotope

Hanwha Chemical

Harvest Moon

Health Canada

Hospira

Hypermarcas

iBio

Instas Pharmaceuticals

Instituto Vital Brazil

Isu Abxis

Johnson & Johnson

Korean Food and Drug Administration (KFDA)

LG Life Sciences

Lonza

Mabion

Mabxience

Medicines and Healthcare Products Regulatory Agency (MHRA)

MedImmune

Merck & Co.

Merck Serono

Ministry of Health, Labour and Welfare (MHLW)

Mochida Pharmaceutical

Mylan

Natco Pharma

National Institute for Health and Care Excellence (NICE)

Nichi-Iko Pharmaceutical Co.

Nippon Kayaku

Novartis

Oncobiologics

Parexel

Pfizer

Pharma Praxis

PhRMA

Plantform

Probiomed

Quintiles

Reliance Life Sciences

Roche

Samsung

Samsung Bioepis

Sandoz

Sanofi

Schnell

Seattle Genetics

Shanghai CP Guojian

Spectrum Pharmaceuticals

Stada

State Food and Drug Administration (SFDA)

Synthon

Teva Pharmaceutical Industries

União Química

Viropro

World Health Organization (WHO)

Wyeth

Zenotech

To order this report:Biopharmaceutical Industry: Biosimilar Monoclonal Antibodies: World Market Prospects 2013-2023

__________________________

Contact Clare: clare@reportlinker.com
US:(339) 368 6001
Intl:+1 339 368 6001

SOURCE Reportlinker